1Stephens LC, Schultheiss TE, Price RE, et al.Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer,1991,67:1539-1543.
2Nagler R, Marmary Y, Fox PC, et al. Irradiation-induced damage to the salivary glands:the role of radox-active iron and copper.Radiat Res,1997,147:468-476.
3Franzen L, Gustafsson H, Sundstrom S, et al. Fractionated irradiation and late change in rat parotid gland: effects on the number of acinar cells, potassium efflux, and amylase secretion. Int J Radiat Biol, 1993,64:93-101.
4Vissink A, Down JD, Konings AWT, et al. Contrasting dose-rate effects of γ-irradiation on rat salivary gland function, Int J Radiat Biol, 1992,61:275-282.
5Greenspan D, Daniels TE. Effectiveness of pilocarpine in post- radiation xerostomia. Cancer,1987,59:1123-1125.
6LeVeque FG, Montgomery M, Potter D, et al. A multicenter,randomized,double-blind,placebo-controlled,dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol, 1993,11:1124-1131.
7Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med, 1993,329:390-395.
8Horiot JC, Lipinski F, Schraub S, et al. Post-radiation severe xerostomia relieved by pilocarpine:a prospective French cooperative study . Radiother Oncol,2000,55:233-239.
9Joensuu H, Bostrom P, Makkonen T. Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. Radiother Oncol,1993,26:33-37.
4Bowman S J, Pillemer S, Jonsson R, et al. Revisiting Sjogrenb syndrome in the new millennium:perspectlves on assessment and outcome measures[J]. Rheumatology,2001,40(10) : 1 - 180.
5KLESTOV AC, WEBBJ, LATTD, et al. Tratment of xerostomia: A double-blind trial in 108 patients with sjogren's syndrome[ J ]. Oral Med, 1981,51 (6) :594 -599.
6Weseott WB, Mira JC, Stareke EN, et al. Alterrations in whole saliva flow rate induced by fractloned radiotherapy [J]. A JR Am J Roentgenol, 1978,130 : 145 - 149.
7Leslie MD, Dische S. The. curly changes in salivary gland function during and after rsdiotherapy given for head and neck cancer[J]. Radiother Oncol, 1994,30:26 - 32.
8Johnson JT,Ferretti GA ,Nethery WJ. Orel pilocerpin for post -inadiation xerostomia in patients with head and neck cancer[J]. N Engl J Med, 1993,329 (6) :390 - 395.
9Cox JD, Pajak TF, Marcial VA, et al. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinoma of the upper aerodigestive tracts: preliminary report of Radiation Therapy Oncology Group Protocol 83-13 [ J ]. Int J Radiat Onco Biol Phys, 1990,18(3 ): 515-521.
10Franchin G, Vaccher E, Talamini R, et al. Nasopharyngeal cancer WHO type Ⅱ -Ⅲ: monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy [ J ].Oral Oncology ,2002 ,38 ( 2 ) : 137-144.
